[Pharmacodynamics and the pharmacokinetic parameters of etmozin in ventricular heart rhythm disorders].
A single dose of 300 mg of ethmosine per os has been found to exert an antiarrhythmic action 1-2 h after its administration in 60% of the patients and may be used to terminate episodes of ventricular arrhythmias. 3-4 h after the beginning of its administration, a complete antiarrhythmic effect was observed in giving a "loading" dose of 500-600 mg of ethmosine at the beginning of the treatment followed by maintenance therapy (200 mg given every 8 hours). To treat patients with ventricular rhythm disturbances, ethmosine may be used in a daily dose of 600-900 mg without side effects.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000378:metabolism*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000378:metabolism*; D005117:Cardiac Complexes, Premature / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006352:Heart Ventricles; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D016293:Moricizine; D010640:Phenothiazines / Q000008:administration & dosage / Q000378:metabolism*; D013614:Tachycardia, Paroxysmal / Q000188:drug therapy / Q000378:metabolism; D013997:Time Factors
D000889:Anti-Arrhythmia Agents; D010640:Phenothiazines; D016293:Moricizine
Farmakodinamika i nekotorye parametry farmakokinetiki étmozina u bol'nykh s zheludochkovymi narusheniiami ritma serdtsa.